The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Benito Simon X since 2005.
This trader's CIK number is 1273306.
At the time of last reporting, Benito Simon X was the Director of Inovio Pharmaceuticals, Inc.. (stock ticker symbol INO).
Also see all insider trading activities at Inovio Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | DRRX | 20,000 | $20,360 | 0 | $0 | 0 | $0 |
| 2017 | DRRX | 0 | $0 | 0 | $0 | 25,000 | $20,500 |
| 2015 | DRRX | 40,000 | $72,280 | 0 | $0 | 0 | $0 |
| 2008 | DRRX | 5,000 | $18,065 | 0 | $0 | 0 | $0 |
| 2005 | DRRX | 15,000 | $47,950 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | INO | 0 | $0 | 0 | $0 | 2,167 | $0 |
| 2024 | INO | 0 | $0 | 0 | $0 | 2,166 | $0 |
| 2023 | INO | 0 | $0 | 0 | $0 | 19,000 | $0 |
| 2022 | INO | 0 | $0 | 6,000 | $19,360 | 24,000 | $13,200 |
| 2021 | INO | 0 | $0 | 8,750 | $92,430 | 8,750 | $31,150 |
| 2020 | INO | 0 | $0 | 8,750 | $139,597 | 16,763 | $40,250 |
| 2019 | INO | 0 | $0 | 0 | $0 | 8,170 | $0 |
| 2018 | INO | 0 | $0 | 3,750 | $19,620 | 11,419 | $13,350 |
| 2017 | INO | 0 | $0 | 0 | $0 | 10,000 | $0 |
| 2016 | INO | 0 | $0 | 6,250 | $64,818 | 6,250 | $55,750 |
| 2015 | INO | 6,000 | $43,260 | 0 | $0 | 0 | $0 |
| 2011 | INO | 20,000 | $11,319 | 0 | $0 | 0 | $0 |
2. Inovio Pharmaceuticals, Inc. (INO)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-12-07 | DRRX | Buy | 20,000 | 1.02 | 20,360 |
| 2017-09-25 | DRRX | Option Ex | 25,000 | .82 | 20,500 |
| 2015-03-10 | DRRX | Buy | 40,000 | 1.81 | 72,280 |
| 2008-11-14 | DRRX | Buy | 5,000 | 3.61 | 18,065 |
| 2005-05-19 | DRRX | Buy | 5,000 | 3.27 | 16,350 |
| 2005-05-19 | DRRX | Buy | 5,000 | 3.27 | 16,350 |
| 2005-05-11 | DRRX | Buy | 5,000 | 3.05 | 15,250 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-21 | INO | Option Ex | 2,167 | .00 | 0 |
| 2024-05-15 | INO | Option Ex | 2,166 | .00 | 0 |
| 2023-05-16 | INO | Option Ex | 19,000 | .00 | 0 |
| 2022-07-20 | INO | Option Ex | 2,000 | 2.20 | 4,400 |
| 2022-07-20 | INO | Sale | 2,000 | 2.25 | 4,500 |
| 2022-05-13 | INO | Option Ex | 18,000 | .00 | 0 |
| 2022-03-16 | INO | Option Ex | 2,000 | 2.20 | 4,400 |
| 2022-03-16 | INO | Sale | 2,000 | 3.16 | 6,320 |
| 2022-01-19 | INO | Sale | 2,000 | 4.27 | 8,540 |
| 2022-01-19 | INO | Option Ex | 2,000 | 2.20 | 4,400 |
| 2021-04-16 | INO | Option Ex | 2,000 | 3.56 | 7,120 |
| 2021-04-16 | INO | Sale | 2,000 | 8.75 | 17,500 |
| 2021-03-16 | INO | Option Ex | 2,000 | 3.56 | 7,120 |
| 2021-03-16 | INO | Sale | 2,000 | 10.41 | 20,820 |
| 2021-02-16 | INO | Sale | 2,000 | 14.68 | 29,360 |
| 2021-02-16 | INO | Option Ex | 2,000 | 3.56 | 7,120 |
| 2021-01-04 | INO | Option Ex | 2,750 | 3.56 | 9,790 |
| 2021-01-04 | INO | Sale | 2,750 | 9.00 | 24,750 |
| 2020-05-20 | INO | Option Ex | 8,750 | 4.60 | 40,250 |
| 2020-05-20 | INO | Sale | 8,750 | 15.95 | 139,597 |
| 2020-05-08 | INO | Option Ex | 8,013 | .00 | 0 |
| 2019-05-11 | INO | Option Ex | 8,170 | .00 | 0 |
| 2018-05-12 | INO | Option Ex | 7,669 | .00 | 0 |
| 2018-04-12 | INO | Sale | 3,750 | 5.23 | 19,620 |
| 2018-04-12 | INO | Option Ex | 3,750 | 3.56 | 13,350 |
| 2017-05-13 | INO | Option Ex | 10,000 | .00 | 0 |
| 2016-05-18 | INO | Sale | 6,250 | 10.37 | 64,818 |
| 2016-05-18 | INO | Option Ex | 6,250 | 8.92 | 55,750 |
| 2015-08-14 | INO | Buy | 6,000 | 7.21 | 43,260 |
| 2011-06-24 | INO | Buy | 20,000 | .57 | 11,319 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Benito Simon X (Director of Inovio Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.